Noopept — Background and Chemical Identity

• Chemical name / synonyms: Noopept; also known as N‑phenylacetyl‑L‑prolylglycine ethyl ester; sometimes “GVS‑111”, “Omberacetam”. Wikipedia+2Wikipedia+2
• CAS number: 157115‑85‑0. Wikipedia+1
• Classification / relationship to other nootropics: Although often grouped with racetams (a class of “nootropic” compounds), Noopept is not a classical racetam (it lacks the 2‑oxo‑pyrrolidine core), but was designed to retain some similar pharmacological properties. Wikipedia+1
• Pro‑drug / metabolite hypothesis: Some studies propose that Noopept acts as a prodrug: upon metabolism it may release a shorter peptide (e.g. cyclic dipeptide) structurally similar to endogenous neuropeptides — possibly contributing to its activity. SpringerLink+1

Preclinical and Clinical Evidence: Effects, Mechanisms, and Biological Activity

• Enhanced cognitive (memory, learning) activity — more potent than classical racetams: Early experimental work suggested that Noopept exerts “mnemotropic” effects (memory‑enhancing) at doses much lower than classical racetams: reportedly up to 1000× lower dose compared to something like Piracetam. ResearchGate+1
• Neuroprotective, antioxidant, anti‑apoptotic effects: In cell‑culture models (e.g. PC12 cells), Noopept protected against toxicity induced by β‑amyloid (a peptide implicated in Alzheimer’s disease). Specifically, it reduced oxidative damage, calcium overload, inhibited activation of apoptotic (cell‑death) pathways, reduced tau hyperphosphorylation, and helped maintain neurite (nerve‑cell projection) integrity. PubMed Central+1
• Potential neurotrophin / plasticity effects: Some studies indicate that Noopept may upregulate neurotrophins — for example increasing expression of proteins like BDNF (Brain‑Derived Neurotrophic Factor) or other growth factors/neuroprotective peptides, possibly supporting neuronal health, resilience, and plasticity. SpringerLink+2Dr.Oracle+2
• Preclinical analgesic / anti‑inflammatory effects: In animal models of inflammation and pain, Noopept administration reportedly decreased cellular apoptosis, modulated microglial (immune‑cell in the brain/spinal cord) activity, reduced hyperalgesia (heightened pain sensitivity), and altered neurotrophin expression — suggesting it might influence neuroimmune responses. PubMed Central
• Some clinical / human‑use reports (limited, not robust): There is mention in older literature or non‑peer‑reviewed reports about use of Noopept in patients with cognitive impairment, cerebrovascular or post‑traumatic brain injury, with claims of improvement in cognitive functions (e.g. memory, attention, recovery) at certain dosages. Active Caldic+2NutraHacker+2
• General tolerability (preclinical/human‑case basis): According to reviews of nootropic drugs, compounds like Noopept tend to be relatively well‑tolerated — side‑effects when reported tend to be relatively mild. PubMed Central+2MDPI+2

Proposed / Potential Benefits (Based on Evidence)

Based on the above studies, the potential benefits of Noopept may include:

• Improved memory, learning, and cognitive performance (especially memory consolidation and retrieval), possibly at relatively low doses compared to older nootropics.
• Neuroprotection — ability to protect nerve cells from toxic insults (e.g., β‑amyloid, oxidative stress, apoptosis), which may be relevant for neurodegenerative disease research (e.g. dementia, Alzheimer’s).
• Enhanced neuroplasticity / neuronal health — via promoting neurotrophins (like BDNF), supporting neuron survival, neurite outgrowth, possibly improved synaptic resilience.
• Potential therapeutic or supportive use in neurodegeneration, brain injury, or cognitive decline — though evidence is limited, preclinical data support further investigation.
• Possible anti‑inflammatory, neuroimmune modulatory, or analgesic effects — might influence microglia activity, neuroinflammation, or pain pathways based on animal data.

Known Risks, Limitations, and Key Concerns

• Lack of robust, high‑quality clinical trials: Although there are some reports and older “clinical pharmacological studies,” the evidence base in humans for safety, efficacy, dose‑response, long‑term effects remains limited and not conclusive. ConsumerLab.com+2Active Caldic+2
• Regulatory status / legality (in many jurisdictions): In many countries (e.g., the U.S.), Noopept is not approved as a therapeutic drug, and its sale / marketing as a supplement or “smart drug” may be prohibited or unregulated. U.S. Food and Drug Administration+2Wikipedia+2
• Potential psychiatric or neuropsychiatric side‑effects if misused: More broadly, use (especially unsupervised) of nootropics has been associated with potential psychiatric adverse effects — for example in a small number of case reports describing mood changes, psychosis, or other neuropsychiatric issues. While not necessarily specific to Noopept, this underscores the uncertainty and risk of unsupervised use. PubMed Central+2PubMed Central+2
• Unknown long-term safety / chronic effects: There is insufficient data on long-term administration (months to years), potential cumulative toxicity, effects on brain structure, neurochemistry, or systemic health.
• Variability in quality / purity when acquired outside research contexts: As with many experimental or “grey‑market” nootropic compounds, there is a risk of contamination, incorrect dosing, or mislabeling — which can amplify risks or lead to unintended effects. PubMed Central+2U.S. Food and Drug Administration+2
• Potential overhyped / exaggerated claims: Marketing often describes Noopept as a “miracle cognition enhancer,” “anti‑aging brain drug,” or “memory booster,” but these claims are typically not backed by high‑quality scientific evidence. The gap between preclinical promise and clinical proof remains large.

Interpretation: Where Noopept Stands Scientifically (As of Now)

Noopept is arguably one of the more widely known synthetic nootropic agents — with a body of preclinical research supporting its potential neuroprotective, neurotrophic, and cognitive‑enhancing effects. Its potency (compared to older racetams) and apparent neuroprotective features make it a candidate of interest for research into neurodegeneration, brain injury, and cognitive decline.

However, from a medical and regulatory standpoint, Noopept remains unproven. The lack of robust, large-scale, long-term human clinical trials means that safety, efficacy, optimal dosing, and long‑term outcomes are not established.

In sum: Noopept may deserve further scientific investigation, but it cannot — as of now — be considered a validated, approved, safe, and effective therapy or “cognitive enhancer” for humans.

For these reasons, Noopept should be regarded as an experimental compound — not a panacea — and only considered within strictly controlled research contexts.

Frequently Asked Questions (FAQ) about Noopept

1. What is Noopept and what is its CAS number?
   • Noopept is N‑phenylacetyl‑L‑prolylglycine ethyl ester (also called GVS‑111 or Omberacetam). Its CAS number is 157115‑85‑0. Wikipedia+1
2. Is Noopept a racetam?
   • While often grouped with racetams (due to similar purported cognitive‑enhancing aims), chemically Noopept does not have the classical 2‑oxo‑pyrrolidine “racetam” core. It is structurally different, though functionally it may share some nootropic mechanisms. Wikipedia+1
3. What does scientific research suggest Noopept might do in the brain?
   • Preclinical research suggests Noopept may enhance memory and learning, promote neuroprotection (against oxidative stress, amyloid toxicity), support neuronal plasticity and neurotrophin expression, and modulate neuroimmune / inflammatory responses. PubMed+3PubMed Central+3SpringerLink+3
4. Has Noopept been studied in humans, and is there evidence it works in people?
   • There are some older pharmacological / clinical‑use reports (e.g., in situations like cognitive impairment, cerebrovascular disorders, recovery after brain injury). However, the evidence is limited, not robust, and insufficient to confirm safety or efficacy. Active Caldic+2ConsumerLab.com+2
5. What are the potential risks or side effects associated with Noopept?
   • Because data are limited, potential risks are uncertain. Some general concerns about nootropics include possible psychiatric side‑effects (mood changes, irritability, insomnia, dependence), especially when misused or taken without medical supervision. PubMed Central+2Dr.Oracle+2
   • Additional risk arises from variability in product purity / quality when sourced outside regulated contexts. PubMed Central+1
6. Is Noopept approved by regulatory authorities (e.g., FDA) for use as a cognitive enhancer or medicine?
   • In many countries (including the U.S.), Noopept is not approved as a therapeutic drug. Its sale as a “dietary supplement” or “smart‑drug” is often unregulated or prohibited. U.S. Food and Drug Administration+2Wikipedia+2
7. Could Noopept be useful in neurodegenerative diseases (e.g., Alzheimer’s) or brain injury?
   • Preclinical data (cell and animal studies) are suggestive of neuroprotective and neuroplasticity‑promoting effects, which makes Noopept a candidate for further research in neurodegeneration or brain injury. However — no conclusive human clinical data exist to support such use.
8. Is Noopept significantly more “potent” than older nootropics like Piracetam?
   • Some studies claim that Noopept exerts similar or better nootropic / neuroprotective effects at much lower doses compared to classical racetams (e.g., Piracetam). Science.gov+2ResearchGate+2
9. Does Noopept have neuroprotective or antioxidant effects beyond cognitive enhancement?
   • Yes — in vitro and preclinical studies show it can reduce oxidative damage, prevent apoptosis (cell death), protect against toxic insults (e.g., amyloid‑related), and support neural cell survival and morphology under stress. PubMed Central+2PubMed+2
10. Given current evidence — is Noopept “safe and effective” for cognitive enhancement?
    • Based on current published literature: No — it is not proven to be safe and effective. The evidence is preliminary, limited, and mainly preclinical. Long-term safety, efficacy, and risk profile remain uncertain. The potential benefits are speculative until validated by rigorous human research.

Key Limitations in Current Knowledge

• The majority of positive results come from in vitro (cell) or animal studies — translation to humans remains unproven.
• Human data are sparse, often outdated, and not from large, controlled, long-term clinical trials.
• Long-term safety, including potential neurological, psychiatric or systemic side effects, remains uncharacterized.
• Quality control and regulation are inconsistent — many products marketed as “nootropics” may be adulterated, mislabeled, or impure.
• The gap between marketing claims (“memory booster,” “anti‑aging brain drug”) and rigorous scientific evidence is large.

Conclusion (As of Current Evidence)

Noopept is a synthetic nootropic compound with a promising profile in preclinical studies — showing memory enhancement, neuroprotection, neuroplasticity, and potential resilience against neurodegenerative insults or injury. Its potency and proposed mechanisms make it an interesting candidate for further research into cognitive disorders, neurodegeneration, or brain recovery therapies.

However, the current evidence does not support Noopept as a safe, effective, and approved therapy or cognitive enhancer for humans. Until robust, well‑controlled human clinical trials are conducted — assessing safety, efficacy, dosing, and long-term effects — any non‑clinical use of Noopept remains speculative and potentially risky.

Accordingly, Noopept should be considered a research chemical, not a validated medical or supplement product.

For these reasons, any interest in Noopept should be restricted to controlled, scientifically‑supervised research settings.

Disclaimer: This document is provided for research and educational purposes only. Noopept is not approved by major regulatory agencies for cognitive enhancement or treatment of any disease. The safety, efficacy, and long-term effects of Noopept are unproven. Use outside regulated research contexts may pose unknown health risks.